HLTH:AU:AU-VanEck Global Healthcare Leaders ETF (AUD)

ETF | Others |

Last Closing

USD 11.31

Change

+0.04 (+0.35)%

Market Cap

USD 0.06B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-05 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

-1.01 (-0.99%)

USD 18.39B
IVV:AU iShares Core S&P 500 AUD

-0.42 (-0.72%)

USD 11.33B
VGS:AU Vanguard MSCI International Sh..

-0.72 (-0.54%)

USD 10.39B
QUAL:AU VanEck Vectors MSCI World ex A..

-0.17 (-0.31%)

USD 7.35B
IOZ:AU Ishares Core S&P/Asx 200

-0.35 (-1.05%)

USD 6.40B
VTS:AU Vanguard US Total Market Share..

-3.35 (-0.78%)

USD 5.71B
STW:AU SPDR® S&P/ASX 200 Fund

-0.72 (-0.97%)

USD 5.54B
NDQ:AU Betashares Nasdaq 100

-0.15 (-0.33%)

USD 5.22B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

+0.25 (+0.63%)

USD 4.86B
A200:AU BetaShares Australia 200

-1.45 (-1.05%)

USD 4.72B

ETFs Containing HLTH:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.44% 68% D+ 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.44% 54% F 58% F
Trailing 12 Months  
Capital Gain 4.24% 52% F 63% D
Dividend Return 0.83% 9% A- 6% D-
Total Return 5.07% 31% F 58% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 1.07% 33% F 46% F
Dividend Return 1.48% 24% F 42% F
Total Return 0.41% 8% B- 7% C-
Risk Return Profile  
Volatility (Standard Deviation) 8.96% 60% D- 90% A-
Risk Adjusted Return 16.48% 21% F 48% F
Market Capitalization 0.06B 15% F 50% F

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.